3/30
08:43 am
mltx
MoonLake Immunotherapeutics (MLTX) had its "buy" rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (MLTX) had its "buy" rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.
3/28
03:45 pm
mltx
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting [Yahoo! Finance]
Low
Report
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting [Yahoo! Finance]
3/28
03:00 pm
mltx
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Low
Report
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
3/23
08:42 am
mltx
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
3/19
08:43 am
mltx
MoonLake Immunotherapeutics (MLTX) was upgraded by Rothschild & Co Redburn from "neutral" to "buy". They now have a $40.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (MLTX) was upgraded by Rothschild & Co Redburn from "neutral" to "buy". They now have a $40.00 price target on the stock.
3/16
08:06 pm
mltx
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? [Yahoo! Finance]
Low
Report
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? [Yahoo! Finance]
3/2
11:54 am
mltx
MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.
Neutral
Report
MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.
3/2
10:38 am
mltx
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]
Low
Report
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]
3/2
08:43 am
mltx
MoonLake Immunotherapeutics (MLTX) had its price target raised by HC Wainwright from $32.00 to $40.00. They now have a "buy" rating on the stock.
Medium
Report
MoonLake Immunotherapeutics (MLTX) had its price target raised by HC Wainwright from $32.00 to $40.00. They now have a "buy" rating on the stock.
2/26
06:28 am
mltx
MoonLake Immunotherapeutics (MLTX) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
MoonLake Immunotherapeutics (MLTX) was upgraded by Zacks Research from "strong sell" to "hold".
2/24
08:02 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at BTIG Research from $24.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at BTIG Research from $24.00 to $30.00. They now have a "buy" rating on the stock.
2/24
08:02 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at Needham & Company LLC from $20.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at Needham & Company LLC from $20.00 to $25.00. They now have a "buy" rating on the stock.
2/24
08:02 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
2/22
11:00 am
mltx
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Low
Report
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
2/20
09:36 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at Royal Bank Of Canada from $10.00 to $12.00. They now have a "sector perform" rating on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at Royal Bank Of Canada from $10.00 to $12.00. They now have a "sector perform" rating on the stock.
2/9
12:27 pm
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
2/3
08:12 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
2/2
08:00 am
mltx
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
Medium
Report
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
1/22
07:48 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.